Heron Therapeuti is a biotechnology business based in the US. Heron Therapeuti shares (HRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Heron Therapeuti employs 126 staff and has a trailing 12-month revenue of around $132.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.10 |
|---|---|
| 52-week range | $0.50 - $3.93 |
| 50-day moving average | $3.31 |
| 200-day moving average | $2.30 |
| Wall St. target price | $6.75 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.55 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.1 from 2024-07-25
| 1 week (2024-07-19) | -4.62% |
|---|---|
| 1 month (2024-06-27) | -9.09% |
| 3 months (2024-04-26) | 26.53% |
| 6 months (2024-01-26) | 24.50% |
| 1 year (2023-07-27) | 101.30% |
|---|---|
| 2 years (2022-07-27) | 8.01% |
| 3 years (2021-07-27) | 12.24 |
| 5 years (2019-07-26) | 17.74 |
| Revenue TTM | $132.1 million |
|---|---|
| Gross profit TTM | $-50,508,000 |
| Return on assets TTM | -18.45% |
| Return on equity TTM | -2408.88% |
| Profit margin | -61.28% |
| Book value | $-0.23 |
| Market Capitalization | $489.6 million |
TTM: trailing 12 months
We're not expecting Heron Therapeuti to pay a dividend over the next 12 months.
Heron Therapeuti's shares were split on a 1:20 basis on 12 January 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heron Therapeuti shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Heron Therapeuti shares which in turn could have impacted Heron Therapeuti's share price.
Over the last 12 months, Heron Therapeuti's shares have ranged in value from as little as $0.5 up to $3.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heron Therapeuti's is 1.806. This would suggest that Heron Therapeuti's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Heron Therapeutics, Inc. , a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A. P.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.